Mabwell (Shanghai) Bioscience Co., Ltd.
Mabwell (Shanghai) Bioscience Co., Ltd.
Explore linked clinical trials.23 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy | squamous cell lung carcinoma | Not yet recruiting | Phase 3 | 2026-09-21 | NCT07831863 | |
| A Phase I Study of 9MW4113 Injection Versus Dupixent® | Healthy Participants | Active, not recruiting | Phase 1 | 2026-08-27 | NCT07791342 | |
| First-in-human Study of 7MW4911 in GI Cancer | GI Cancers | Recruiting | Phase 1 / Phase 2 | 2026-08-21 | NCT07216560 | |
| An Exploratory Study to Evaluate the Tolerability and Safety of MWAV201 in Subjects With Wilson Disease | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Nutritional and Metabolic Diseases, Wilson disease, basal ganglia disorder, brain disorder, central nervous system disorder, hereditary disease, inborn errors of metabolism, inborn metal metabolism disorder, inherited neurodegenerative disorder, liver disorder, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease | Active, not recruiting | Not applicable | 2026-08-12 | NCT06663878 | |
| A Phase II Study of 9MW3811 in Patients With Pathological Scar | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, severe cutaneous adverse reaction | Recruiting | Phase 2 | 2026-05-08 | NCT07576608 | |
| A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Not yet recruiting | Phase 3 | 2026-04-30 | NCT07556848 | |
| A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 1 | 2026-03-17 | NCT06908928 | |
| A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors | Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-03-12 | NCT07466160 | |
| 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urothelial carcinoma | Recruiting | Phase 2 | 2026-01-02 | NCT07314723 | |
| First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors | Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-12-29 | NCT07265622 | |
| A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 2 | 2025-12-18 | NCT07292714 | |
| Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD). | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Active, not recruiting | Phase 1 / Phase 2 | 2025-05-20 | NCT06175351 | |
| A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 1 | 2025-05-11 | NCT06752746 | |
| A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors | Solid Tumors | Not yet recruiting | Phase 1 / Phase 2 | 2025-04-27 | NCT06947226 | |
| 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors | Gynecological Malignancies | Not yet recruiting | Phase 1 / Phase 2 | 2025-04-15 | NCT06926998 | |
| A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer | Advanced Urothelial Carcinoma | Recruiting | Phase 3 | 2025-04-13 | NCT06196736 | |
| 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, renal pelvis/ureter urothelial carcinoma, transitional cell carcinoma, urothelial carcinoma | Recruiting | Phase 2 | 2025-03-21 | NCT06823427 | |
| A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, thalassemia | Recruiting | Phase 1 | 2025-01-14 | NCT06772766 | |
| A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2025-01-10 | NCT06492005 | |
| A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 3 | 2024-11-22 | NCT06692166 | |
| Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Active, not recruiting | Phase 1 / Phase 2 | 2024-11-21 | NCT05990452 | |
| 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urothelial carcinoma | Recruiting | Phase 3 | 2024-09-19 | NCT06592326 | |
| 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer | Advanced Urothelial Carcinoma | Recruiting | Phase 1 / Phase 2 | 2024-09-19 | NCT06079112 |